This data supports a growing body of evidence from experimental models of PH suggesting attractiveness of TGF-β signaling as a novel molecular target pathway for therapeutic intervention in PAH [8,53,54,55]. The gene discussed is TGFB1; the disease is pulmonary arterial hypertension.